Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-09 09:22 am Purchase | 13G | Nabriva Therapeutics plc NBRV | FMR LLC | 2,215,958 3.847% | 786,699 (+55.04%) | View |
| 2021-11-19 12:57 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Lincoln Park Capital Fund LLC | 4,512,589 7.96% | 4,512,589 (New Position) | View |
| 2021-02-08 10:35 am Purchase | 13G | Nabriva Therapeutics plc NBRV | FMR LLC | 1,429,259 6.78% | 1,429,259 (New Position) | View |
| 2020-02-12 4:32 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Longitude Capital Partners II LLC | 4,256,527 4.5% | 244,152 (+6.08%) | View |
| 2020-02-07 11:26 am Purchase | 13G | Nabriva Therapeutics plc NBRV | FMR LLC | 6,131,900 6.485% | 6,131,900 (New Position) | View |
| 2019-12-26 4:01 pm Unchanged | 13D | Nabriva Therapeutics plc NBRV | ORBIMED ADVISORS LLC | 4,644,600 4.9% | 0 (Unchanged) | View |
| 2019-12-06 4:46 pm Unchanged | 13D | Nabriva Therapeutics plc NBRV | ORBIMED ADVISORS LLC | 4,644,600 5.9% | 0 (Unchanged) | View |
| 2019-08-14 4:31 pm Sale | 13G | Nabriva Therapeutics plc NBRV | Vivo Capital VIII LLC | 3,528,566 4.8% | -1,272,767 (-26.51%) | View |
| 2019-07-01 4:52 pm Sale | 13G | Nabriva Therapeutics plc NBRV | Novo Holdings A/S | 3,446,564 4.74% | -1,257,156 (-26.73%) | View |
| 2019-02-14 4:48 pm Sale | 13G | Nabriva Therapeutics plc NBRV | HBM Healthcare Investments (Cayman) Ltd. | 1,834,007 11% | -500,001 (-21.42%) | View |
| 2019-02-14 3:25 pm Unchanged | 13G | Nabriva Therapeutics plc NBRV | Vivo Capital VIII LLC | 4,801,333 7.2% | 0 (Unchanged) | View |
| 2019-02-14 3:08 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Frazier Healthcare VII L.P. | 4,256,526 6.4% | 244,152 (+6.08%) | View |
| 2019-02-14 08:49 am Sale | 13G | Nabriva Therapeutics plc NBRV | venBio Global Strategic Fund II L.P. | 0 0% | -2,122,962 (Position Closed) | View |
| 2019-02-11 11:55 am Sale | 13G | Nabriva Therapeutics plc NBRV | WELLINGTON MANAGEMENT GROUP LLP | 0 0% | -3,594,568 (Position Closed) | View |
| 2019-02-08 09:21 am Sale | 13G | Nabriva Therapeutics plc NBRV | WELLINGTON MANAGEMENT GROUP LLP | 3,594,568 5.37% | -1,437,108 (-28.56%) | View |
| 2019-02-01 11:45 am Purchase | 13G | Nabriva Therapeutics plc NBRV | Novo Holdings A/S | 4,703,720 7.02% | 1,778,898 (+60.82%) | View |
| 2018-08-10 09:41 am Sale | 13G | Nabriva Therapeutics plc NBRV | WELLINGTON MANAGEMENT GROUP LLP | 5,031,676 7.57% | -108,613 (-2.11%) | View |
| 2018-08-07 4:51 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Longitude Capital Partners II LLC | 4,012,375 6% | 4,012,375 (New Position) | View |
| 2018-08-06 4:32 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Vivo Capital VIII LLC | 4,801,333 7.2% | 727,143 (+17.85%) | View |
| 2018-08-02 8:20 pm Purchase | 13G | Nabriva Therapeutics plc NBRV | Frazier Healthcare VII L.P. | 4,012,374 6% | 4,012,374 (New Position) | View |